Preliminary program outline
| Wednesday | September 25 |
|---|---|
| 09.00-10.00 | Registration |
| Opening Session | |
| 10.15-10.20 | Welcome (TBD) |
| 10.20-10.50 | Opening Plenary (Pl1) The Russian HIV epidemic (Vadim Pokrovskiy, Russia) |
| 10.50-11.00 | Discussion |
| Abstract Session I | |
| 11.00-11.15 | Oral 1 (10 min + 5 min discussion) |
| 11.15-11.30 | Oral 2 |
| 11.30-11.45 | Oral 3 |
| 11.45-12.00 | Oral 4 |
| 12.00-13.00 | Lunch |
| 13.00-13.50 | BHIVA and HIV Nordic joint session – Evolving HIV treatment and care |
| New drugs and treatment strategies (Chloe Orkin, UK) | |
| Cervical cancer and dysplasia in HIV (Christina Carlander, Sweden) | |
| Discussion | |
| Plenary session I – HIV treatment and clinical challenges | |
| 13.50-14.15 | Plenary (Pl2) INSTI adverse events – what is the truth? (Jan Gerstoft, Denmark) |
| 14.15-14.25 | Discussion |
| 14.25-14.40 | Short Break |
| 14.40-15.10 | Plenary (Pl3) Update on ART and birth defects (Lynne M Mofenson, USA) |
| 15.10-15.20 | Discussion |
| 15.20-15.50 | Plenary (Pl4) Resurgent STIs in HIV Care and Prevention (Sharon Walmsley, Canada) |
| 15.50-16.00 | Discussion |
| 16.00-16.30 | Coffee and exhibition/posters |
| 16.30-17.30 | Satellite Symposium 1 – MSD The role of NNRTI in modern ART Föreläsare: Magnus Gisslén (Sweden) and Emmi Andersson (Sweden) |
| 17.30-17.45 | Short break |
| 17.45-18.45 | Satellite Symposium 2 – Gilead HIV Presenting late with HIV in the Nordics: What can we do better to reduce disease and transmission burden? An interactive session with panel discussion and questions for the audience. Moderator: Ole Kirk, Rigshospitalet (Denmark) Panel: Anders Sönnerborg, Karolinska Institutet (Sweden), Pia Kivelä, Helsinki University Hospital (Finland), Magnús Gottfreðsson, National University Hospital of Iceland |
| 18.45- | Poster Exhibition with cheese and snacks |
| Thursday | September 26 |
|---|---|
| 08.00-09.00 | Satellite Symposium 3 – GSK/ViiV Why use 3 when 2 could be enough? Moderator: Prof Magnus Gisslén Two drug regimens (2DRs) in the Nordic countries, experience and guidelines (Prof Magnus Gisslén, Sweden) Treatment with less drugs – Why? How? When? (Prof Chloe Orkin UK) |
| 09.00-09.10 | Short break |
| Plenary Session II – Reservoirs and Cure | |
| 09.10-09.40 | Plenary (Pl5) New insights in formation of the HIV reservoir (Ron Swanstrom, USA) |
| 09.40-09.50 | Discussion |
| 09.50-10.20 | Plenary (Pl6) Viral reservoirs in tissue (Jacob Estes, USA) |
| 10.20-10.30 | Discussion |
| 10.30-11.00 | Coffee and Poster exhibition |
| 11.00-11.30 | Plenary (Pl7) Functional Cure of HIV (Lucy Dorrell, Oxford, UK) |
| 11.30-11.40 | Discussion |
| Plenary Session III – HIV control | |
| 11.40-12.10 | Plenary (Pl8) Mechanisms of elite control (Beatriz Mothe, Spain) |
| 12.10-12.20 | Discussion |
| 12.20-12.50 | Plenary (Pl9) Mechanisms of post-treatment control (John Frater, UK) |
| 12.50-13.00 | Discussion |
| 13.00-14.00 | Lunch |
| Plenary Session IV – Last year’s most important achievements in the HIV research field | |
| 14.00-14.30 | Plenary (Pl10) Top 5 in basic HIV research 2018-2019 (Marianne Jansson, Sweden) |
| 14.30-15.00 | Plenary (Pl11) Top 5 in clinical HIV research 2018-2019 (Terese Katzenstein, Denmark) |
| Plenary Session V – TBD | |
| 15.00-15.20 | Plenary (Pl12) Update on INSTI resistance (Anne-Geneviève Marcelin, France) |
| 15.20-15.30 | Discussion |
| 15.30-15.50 | Plenary (Pl13) Significance of low-level viremia during antiretroviral treatment (Anders Sönnerborg, Sweden) |
| 15.50-16.00 | Discussion |
| 16.00-16.20 | Coffee and Poster exhibition |
| 16.20-16.30 | HIV & Hepatitis Nordic Conference 2019 Abstract Award (TBD) |
| 16.30-17.30 | Satellite Symposium 4 – Gilead Hepatitis |
| 17.30-17.45 | Short break |
| 17.45-18.45 | Satellite Symposium 5 – TBD |
| Conference Dinner | |
| Friday | September 27 |
|---|---|
| 08.00-09.00 | Satellite Symposium 6 – TBD |
| Plenary Session VI – Last year’s most important achievements in the hepatitis field | |
| 09.00-09.30 | Plenary (Pl14) Top 5 in hepatitis research 2017/18 (Ola Weiland, Sweden) |
| 09.30-09.40 | Discussion |
| Abstract Session II | |
| 09.40-09.55 | Oral 5 (10 + 5 min discussion) |
| 09.55-10.10 | Oral 6 |
| 10.10-10.45 | Coffee and Poster exhibition |
| Session VII – HCV treatment among people who inject drugs - experiences from Norway, Denmark and Sweden (Martin Kåberg, Sweden & Marianne Alanko, Sweden) |
|
| 10.45-12.15 | Olav Dalgard (Norway) Anne Øvrehus (Denmark) Anna Jerkeman (Sweden) |
| 12.15-13.15 | Lunch |
| Plenary Session VIII – Hepatitis B/D | |
| 13.15-13.35 | Plenary 15 Immunological aspects of stopping NUC treatment in HBV (Niklas Björkström, Sweden) |
| 13.35-13.45 | Discussion |
| 13.45-14.05 | Plenary 16 Future options for treatment of hepatitis delta (Maria Buti, Spain) |
| 14.05-14.15 | Discussion |
| 14.15-14.35 | Plenary 17 Hepatitis B cure – progress, obstacles and definitions (Johannes Vermehren, Germany) |
| 14.35-14.45 | Discussion |
| 14.45-15.00 | Short break |
| Plenary Session IX – Hepatitis C | |
| 15.00-15.20 | Plenary 18 Aspects on HCV vaccine development (Jannick Prentø, Denmark) |
| 15.20-15.30 | Discussion |
| 15.30-15.50 | Plenary 19 Eradicating HCV, a global perspective (John Dillon, UK) |
| 15.50-16.00 | Discussion |
| 16.00-16.15 | Concluding remarks |